The role of recombinant activated Factor VII in major obstetric haemorrhage: The Farnborough experience

References

• Ahonen J, Jokela R. Recombinant factor VIIa for life-threatening post-partum haemorrhage. British Journal of Anaesthesia 2005; 94: 592
   PubMed Web of Science ®Google Scholar
• Aledort L M. Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activity. Journal of Thrombosis and Haemostasis 2004; 2: 1700–1708
   PubMed Web of Science ®Google Scholar
• Barletta J F, Ahrens C L, Tyburski J G, Wilson R F. A review of recombinant factor VII for refractory bleeding in nonhemophilic trauma patients. Journal of Trauma 2005; 58: 646–651
   PubMed Web of Science ®Google Scholar
• Boffard K D, Bruno R, Warren B, Choong P, Rizoli S, Rossaint R, , for the NovoSeven Trauma Study Group, et al. Recombinant factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: two parallel randomized, placebo-controlled, double-blind clinical trials. Journal of Trauma 2005; 59: 6–18
   Google Scholar
• Bouwmeester F W, Jonkhoff A R, Verheijen R HM, van-Geijn H P. Successful treatment of life-threatening postpartum haemorrhage with recombinant activated factor VII. Obstetrics and Gynecology 2003; 101: 1174–1176
   PubMed Web of Science ®Google Scholar
• Brice A, Hilbert U, Roger-Christoph S, Fernandez H, Dumenil A S, Descorps-Declère A, et al. Recombinant activated factor VII as a lifesaving therapy for severe postpartum haemorrhage unresponsive to conservative traditional management. Annales Francaises D'anesthesie et de Reanimation 2004; 23: 1084–1088
   PubMedGoogle Scholar
• Butenas S, Brummel K E, Branda R F, et al. Mechanism of factor VIIa-dependent coagulation in hemophilia blood. Blood 2002; 99: 923–930
   PubMedGoogle Scholar
• Eskandari N, Feldman N, Greenspoon J S. Factor VII deficiency in pregnancy treated with recombinant factor VIIa. Obstetrics and Gynecology 2002; 99: 935–937
   PubMed Web of Science ®Google Scholar
• Hedner U, Kisiel W. Use of human factor VIIa in the treatment of two hemophilia A patients with high-titer inhibitors. Journal of Clinical Investigation 1983; 71: 1836–1841
   PubMed Web of Science ®Google Scholar
• Hunault M, Bauer K A. Recombinant factor VIIa for the treatment of congenital factor VII deficiency. Seminars in Thrombosis and Hemostasis 2000; 26: 401–405
   PubMed Web of Science ®Google Scholar
• Ingerslev J. Efficacy and safety of recombinant factor VIIa in the prophylaxis of bleeding in various surgical procedures in hemophilic patients with factor VIII and factor IX inhibitors. Seminars in Thrombosis and Hemostasis 2000; 26: 425–432
   PubMed Web of Science ®Google Scholar
• Kale A, Bayhan G, Yalinkaya A, Yayla J M. The use of recombinant factor VIIa in a primigravida with Glanzmann's thrombasthenia during delivery. Journal of Perinatal Medicine 2004; 32: 456–458
   PubMedGoogle Scholar
• Levi M, Peters M, Büller H R. Efficacy and safety of recombinant factor VIIa for treatment of severe bleeding: A systematic review. Critical Care Medicine 2005; 33: 883–890
   PubMed Web of Science ®Google Scholar
• Lim Y, Loo C C, Chia V, Fun W. Recombinant factor VIIa after amniotic fluid embolism and disseminated intravascular coagulopathy. International Journal Gynecology and Obstetrics 2004; 87: 178–179
   PubMed Web of Science ®Google Scholar
• Lusher J, Ingerslev J, Roberts H, Hedner U. Clinical experience with recombinant factor VIIa. Blood Coagulation and Fibrinolysis 1998; 9: 119–128
   PubMed Web of Science ®Google Scholar
• Martinowitz U, Kenet G, Segal E, Luboshitz J, Lubetsky A, Ingerslev J, et al. Recombinant activated factor VII for adjunctive haemorrhage control in trauma. Journal of Trauma 2001; 51: 431–438
   PubMed Web of Science ®Google Scholar
• Martinowitz U, Michaelson M. Guidelines for the use of recombinant activated factor VII (rFVIIa) in uncontrolled bleeding: a report by the Israeli Multidisciplinary rFVIIa Task Force. Journal of Thrombosis and Haemostasis 2005; 3: 640–648
   PubMed Web of Science ®Google Scholar
• Meng Z H, Wolberg A S, Monroe D M, III, Hoffman M. The effect of temperature and pH on the activity of factor VIIa: implications for the efficacy of high-dose factor VIIa in hypothermic and acidotic patients. Journal of Trauma 2003; 55: 886–891
   PubMedGoogle Scholar
• Mohr A M, Holcomb J B, Dutton R P, Duranteau J. Recombinant activated factor VIIa and haemostasis in critical care: a focus on trauma. Critical Care 2005; 9: S37–S42
   PubMedGoogle Scholar
• Mousa H A, Walkinshaw S. Major postpartum haemorrhage. Current Opinions in Obstetrics and Gynecology 2001; 13: 595–603
   PubMed Web of Science ®Google Scholar
• O'Neill P A, Bluth M, Gloster E S, Wali D, Priovolos S, DiMaio T M, et al. Successful use of recombinant activated factor VII for trauma-associated haemorrhage in a patient without preexisting coagulopathy. Journal of Trauma 2002; 52: 400–405
   PubMedGoogle Scholar
• RCOG. Guideline no. 12. Confidential Enquiry into Maternal and Child Health. RCOG Press, London 2004
   Google Scholar
• Segal I Y, Shemesh R, Blumenthal B, Yoffe N, Laufer Y, Ezra I, et al. Treatment of obstetric haemorrhage with recombinant activated factor VII (rFVIIa). Archives of Gynecology and Obstetrics 2003; 268: 266–267
   PubMedGoogle Scholar
• Sobieszczyk S, Breborowicz G H, Markwitz W, Mallinger S, Adamski D, Kruszynski Z. Effect of recombinant activated factor VII (RFVIIA; NovoSeven) in a patient in hemorrhagic shock after obstetrical hysterectomy. Ginekologia Polska 2002; 73: 230–233
   PubMedGoogle Scholar
• Stein S C, Chen X H, Sinson G P, Smith D H. Intravascular coagulation: a major secondary insult in nonfatal traumatic brain injury. Journal of Neurosurgery 2002; 97: 1373–1377
   PubMed Web of Science ®Google Scholar
• Tanchev S, Platikanov V, Karadimov D. Administration of recombinant factor VIIa for the management of massive bleeding due to uterine atonia in the post-placental period. Acta Obstetricia et Gynecologica Scandinavica 2005; 84: 402–403
   PubMed Web of Science ®Google Scholar
• ten Cate H, Bauer K A, Levi M, Edgington T S, Sublett R D, Barzegar S, et al. The activation of factor X and prothrombin by recombinant factor VIIa in vivo is mediated by tissue factor. Journal of Clinical Investigation 1993; 92: 1207–1212
   PubMed Web of Science ®Google Scholar
• Waterstone M, Bewley S, Wolfe C. Incidence and predictors of severe obstetric morbidity: Case-control study. British Medical Journal 2001; 322: 1089–1094
   PubMed Web of Science ®Google Scholar